These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 17806064)

  • 21. Impact of transmission of drug-resistant HIV on the course of infection and the treatment success. Data from the German HIV-1 Seroconverter Study.
    Poggensee G; Kücherer C; Werning J; Somogyi S; Bieniek B; Dupke S; Jessen H; Hamouda O;
    HIV Med; 2007 Nov; 8(8):511-9. PubMed ID: 17944684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV is associated with thrombophilia and high D-dimer in children and adolescents.
    Pontrelli G; Martino AM; Tchidjou HK; Citton R; Mora N; Ravà L; Tozzi AE; Palma P; Muraca M; Franco E; Rossi P; Bernardi S
    AIDS; 2010 May; 24(8):1145-51. PubMed ID: 20168205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
    Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
    Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.
    Cozzi-Lepri A; Phillips AN; Clotet B; Mocroft A; Ruiz L; Kirk O; Lazzarin A; Wiercinska-Drapalo A; Karlsson A; Lundgren JD;
    AIDS; 2008 Oct; 22(16):2187-98. PubMed ID: 18832882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genotypic antiretroviral drug resistance testing at low viral loads in the UK.
    Cane PA; Kaye S; Smit E; Tilston P; Kirk S; Shepherd J; Hopkins M; Zhang H; Geretti AM
    HIV Med; 2008 Oct; 9(8):673-6. PubMed ID: 18557948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database study.
    Keiser PH; Nassar N
    Int J STD AIDS; 2008 Aug; 19(8):561-2. PubMed ID: 18663047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. When to initiate HIV therapy: a control theoretic approach.
    Jeffrey AM; Xia X; Craig IK
    IEEE Trans Biomed Eng; 2003 Nov; 50(11):1213-20. PubMed ID: 14619991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug-drug interactions involving new antiretroviral drugs and drug classes.
    Soodalter J; Sousa M; Boffito M
    Curr Opin Infect Dis; 2009 Feb; 22(1):18-27. PubMed ID: 19532077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Determination of serum levels of antiretroviral drugs].
    Kurowski M
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():62-4. PubMed ID: 15373053
    [No Abstract]   [Full Text] [Related]  

  • 30. Emerging antiretroviral drug interactions.
    Pham PA; Flexner C
    J Antimicrob Chemother; 2011 Feb; 66(2):235-9. PubMed ID: 21131695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Analysis of the duration of and reasons for changing the first combination of antiretroviral therapy].
    Martín MT; Rovira M; Massanes M; del Cacho E; Carcelero E; Tuset M; Codina C; Miro JM; Gatell JM; Ribas J
    Farm Hosp; 2010; 34(5):224-30. PubMed ID: 20663703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decrease in lipoatrophy in a pilot study using a short-term treatment interruption strategy for 48 weeks in São Paulo, Brazil.
    Gosuen GC; Turcato G; Salomao R; Lewi DS; Diaz RS
    AIDS Res Hum Retroviruses; 2012 Aug; 28(8):747-8. PubMed ID: 22220684
    [No Abstract]   [Full Text] [Related]  

  • 33. A case of cerebrospinal fluid viral escape on a dual antiretroviral regimen: worth the risk?
    Mangioni D; Muscatello A; Sabbatini F; Soria A; Rossi M; Bisi L; Squillace N; De Grandi C; Gori A; Bandera A
    Clin Infect Dis; 2014 Dec; 59(11):1655-6. PubMed ID: 25156113
    [No Abstract]   [Full Text] [Related]  

  • 34. Ask the experts.
    Kaiser JD
    Explore (NY); 2006; 2(5):471-2. PubMed ID: 16979115
    [No Abstract]   [Full Text] [Related]  

  • 35. Long-term follow-up of an HIV-infected patient with reactive arthritis treated with infliximab.
    Gaylis NB
    J Clin Rheumatol; 2012 Apr; 18(3):153-4. PubMed ID: 22426582
    [No Abstract]   [Full Text] [Related]  

  • 36. Notes on the road to perfection; use of nevirapine in combination antiretroviral therapy for children with perinatal nevirapine exposure.
    Krogstad P
    AIDS; 2015 Aug; 29(13):1715-6. PubMed ID: 26372283
    [No Abstract]   [Full Text] [Related]  

  • 37. QT interval prolongation and antiretroviral treatment: another point of interest.
    Chinello P; Petrosillo N
    Clin Infect Dis; 2007 May; 44(10):1388-9; author reply 1389-91. PubMed ID: 17443482
    [No Abstract]   [Full Text] [Related]  

  • 38. Nevirapine-induced fulminant hepatitis.
    Maniar JK; Shah SR; Verma R; Kamath R; Gupte P; Maniar A
    J Assoc Physicians India; 2006 Dec; 54():957-8. PubMed ID: 17334017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV therapy--what do we know, and when do we know it?
    Skolnik PR
    N Engl J Med; 2003 Dec; 349(24):2351-2. PubMed ID: 14668462
    [No Abstract]   [Full Text] [Related]  

  • 40. Interactions of antiretroviral drugs with anti-infectives and other antiretrovirals.
    Pontali E
    Chemotherapy; 2007; 53(1):26-9. PubMed ID: 17192710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.